WO2002074783A3 - Modified interferon beta with reduced immunogenicity - Google Patents

Modified interferon beta with reduced immunogenicity Download PDF

Info

Publication number
WO2002074783A3
WO2002074783A3 PCT/EP2002/002925 EP0202925W WO02074783A3 WO 2002074783 A3 WO2002074783 A3 WO 2002074783A3 EP 0202925 W EP0202925 W EP 0202925W WO 02074783 A3 WO02074783 A3 WO 02074783A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon beta
polypeptides
reduced immunogenicity
modified interferon
modified
Prior art date
Application number
PCT/EP2002/002925
Other languages
French (fr)
Other versions
WO2002074783A2 (en
Inventor
Francis J Carr
Graham Carter
Tim Jones
John Watkins
Matthew Baker
Original Assignee
Merck Patent Gmbh
Francis J Carr
Graham Carter
Tim Jones
John Watkins
Matthew Baker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03008310A priority Critical patent/MXPA03008310A/en
Priority to BR0208041-9A priority patent/BR0208041A/en
Priority to KR10-2003-7011997A priority patent/KR20030084992A/en
Priority to EP02726180A priority patent/EP1368377A2/en
Priority to CA002441095A priority patent/CA2441095A1/en
Priority to US10/471,894 priority patent/US7381795B2/en
Application filed by Merck Patent Gmbh, Francis J Carr, Graham Carter, Tim Jones, John Watkins, Matthew Baker filed Critical Merck Patent Gmbh
Priority to JP2002573792A priority patent/JP2004529633A/en
Priority to PL02362870A priority patent/PL362870A1/en
Priority to HU0303534A priority patent/HUP0303534A3/en
Publication of WO2002074783A2 publication Critical patent/WO2002074783A2/en
Publication of WO2002074783A3 publication Critical patent/WO2002074783A3/en
Priority to US12/077,120 priority patent/US7615615B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human interferon beta to result in proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
PCT/EP2002/002925 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity WO2002074783A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR0208041-9A BR0208041A (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
KR10-2003-7011997A KR20030084992A (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
EP02726180A EP1368377A2 (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
CA002441095A CA2441095A1 (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
US10/471,894 US7381795B2 (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
MXPA03008310A MXPA03008310A (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity.
JP2002573792A JP2004529633A (en) 2001-03-15 2002-03-15 Modified human interferon beta with reduced immunogenicity
PL02362870A PL362870A1 (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
HU0303534A HUP0303534A3 (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity
US12/077,120 US7615615B2 (en) 2001-03-15 2008-03-17 Modified interferon beta with reduced immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106539 2001-03-15
EP01106539.8 2001-03-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10471894 A-371-Of-International 2002-03-15
US12/077,120 Division US7615615B2 (en) 2001-03-15 2008-03-17 Modified interferon beta with reduced immunogenicity

Publications (2)

Publication Number Publication Date
WO2002074783A2 WO2002074783A2 (en) 2002-09-26
WO2002074783A3 true WO2002074783A3 (en) 2003-08-28

Family

ID=8176796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002925 WO2002074783A2 (en) 2001-03-15 2002-03-15 Modified interferon beta with reduced immunogenicity

Country Status (13)

Country Link
US (2) US7381795B2 (en)
EP (1) EP1368377A2 (en)
JP (1) JP2004529633A (en)
KR (1) KR20030084992A (en)
CN (1) CN1496369A (en)
BR (1) BR0208041A (en)
CA (1) CA2441095A1 (en)
HU (1) HUP0303534A3 (en)
MX (1) MXPA03008310A (en)
PL (1) PL362870A1 (en)
RU (1) RU2003129072A (en)
WO (1) WO2002074783A2 (en)
ZA (1) ZA200307992B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008310A (en) * 2001-03-15 2003-12-11 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity.
US20030198624A1 (en) * 2002-03-02 2003-10-23 Mohapatra Shyam S. Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer
US7354908B2 (en) * 2002-04-30 2008-04-08 University Of South Florida Materials and methods for prevention and treatment of RNA viral diseases
US20050220800A1 (en) * 2002-05-01 2005-10-06 Scott Power D Cytokines and cytokine receptors with reduced immunogenicity
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2516188C (en) * 2003-02-14 2012-04-17 University Of South Florida Chitosan-derivatives for gene delivery and expression
EP1636256A2 (en) * 2003-06-10 2006-03-22 Xencor, Inc. Interferon variants with improved properties
US20050266093A1 (en) * 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
CA3001783C (en) 2007-01-30 2020-09-08 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modified toxins
KR20120030383A (en) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 Antibody fusion proteins with modified fcrn binding sites
RU2636456C2 (en) 2011-10-01 2017-11-23 Глитек, Инк. Glycosylated polypeptide and its pharmaceutical composition
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4738844A (en) * 1983-07-01 1988-04-19 G. D. Searle & Co. Modified (1-28) beta interferons
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287491B6 (en) * 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Interferon-beta-1 fusion proteins and their use
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
MXPA03008310A (en) * 2001-03-15 2003-12-11 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4738844A (en) * 1983-07-01 1988-04-19 G. D. Searle & Co. Modified (1-28) beta interferons
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTUVIA Y ET AL: "RANKING POTENTIAL BINDING PEPTIDES TO MHC MOLECULES BY A COMPUTATIONAL THREADING APPROACH", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 249, no. 1, 1995, pages 244 - 250, XP000925520, ISSN: 0022-2836 *
KERN FLORIAN ET AL: "T-cell epitope mapping by flow cytometry", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 8, August 1998 (1998-08-01), pages 975 - 978, XP002155683, ISSN: 1078-8956 *
KWOK W W ET AL: "Rapid epitope identification from complex class-II-restricted T-cell antigens", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 22, no. 11, 1 November 2001 (2001-11-01), pages 583 - 588, XP004319746, ISSN: 1471-4906 *
PORTER A G ET AL: "NOVEL MODIFIED BETA INTERFERONS GENE CLONING EXPRESSION AND BIOLOGICAL ACTIVITY IN BACTERIAL EXTRACTS", DNA (NEW YORK), vol. 5, no. 2, 1986, pages 137 - 148, XP009004132, ISSN: 0198-0238 *
STEWART A G ET AL: "Chemical mutagenesis of human interferon-beta: construction, expression in E. coli, and biological activity of sodium bisulfite-induced mutations.", DNA (MARY ANN LIEBERT, INC.) UNITED STATES APR 1987, vol. 6, no. 2, April 1987 (1987-04-01), pages 119 - 128, XP009004161, ISSN: 0198-0238 *

Also Published As

Publication number Publication date
US7615615B2 (en) 2009-11-10
HUP0303534A3 (en) 2005-12-28
PL362870A1 (en) 2004-11-02
WO2002074783A2 (en) 2002-09-26
MXPA03008310A (en) 2003-12-11
EP1368377A2 (en) 2003-12-10
KR20030084992A (en) 2003-11-01
RU2003129072A (en) 2005-04-20
CA2441095A1 (en) 2002-09-26
US20090043076A1 (en) 2009-02-12
US7381795B2 (en) 2008-06-03
CN1496369A (en) 2004-05-12
JP2004529633A (en) 2004-09-30
BR0208041A (en) 2004-02-25
ZA200307992B (en) 2005-01-14
HUP0303534A2 (en) 2004-01-28
US20050054052A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
WO2001026681A3 (en) Method of obtaining cellular immune responses from proteins
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
WO2002070548A3 (en) Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
WO2002070698A3 (en) Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
WO2003006047A3 (en) Methods for reducing immunogenicity of polypeptides
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
WO2002077034A3 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
WO2004035602A3 (en) Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
WO2002074808A3 (en) Modified insulin with reduced immunogenicity
EP1173476A4 (en) Soybean protein nutraceuticals
HUP0400698A2 (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
BR0207017A (en) Modified keratinocyte growth factor (kgf) with reduced immunogenicity
HUP0402334A2 (en) Modified human growth hormone
WO2003093298A3 (en) Immunogenic peptides
HUP0402160A2 (en) T-cell epitodes in carboxypeptidase g2
WO2002078607A3 (en) Mucin peptide with immunoenhancing properties
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
IL85204A0 (en) Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002726180

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002256681

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2441095

Country of ref document: CA

Ref document number: 10471894

Country of ref document: US

Ref document number: PA/a/2003/008310

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 028065972

Country of ref document: CN

Ref document number: 1020037011997

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002573792

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/07992

Country of ref document: ZA

Ref document number: 200307992

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002726180

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642